Thalidomide and analogues: Potential for immunomodulation of inflammatory and neoplastic dermatologic disorders

Journal of Drugs in Dermatology

Volumn 9, Issue 7, 2010, Pages 814-826

  Ladizinski, Barry ^a   Shannon, Edward J ^b   Sanchez, Miguel R ^c   Levis, William R ^d  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d BELLEVUE HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; DAPSONE; DIPEPTIDYL CARBOXYPEPTIDASE; GAMMA INTERFERON; IMMUNOGLOBULIN M; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 2; LENALIDOMIDE; MESSENGER RNA; PENTOXIFYLLINE; PLACEBO; POMALIDOMIDE; PREDNISONE; RHO FACTOR; TEMOZOLOMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; DRUG DERIVATIVE;

ACTINIC PRURIGO; ALLERGIC ENCEPHALOMYELITIS; APHTHOUS STOMATITIS; APHTHOUS ULCER; ATOPIC DERMATITIS; BEHCET DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CUTANEOUS T CELL LYMPHOMA; DELAYED HYPERSENSITIVITY; DISCOID LUPUS ERYTHEMATOSUS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM LEPROSUM; FAMILIAL MEDITERRANEAN FEVER; GRAFT VERSUS HOST REACTION; HISTIOCYTOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNOMODULATION; KAPOSI SARCOMA; LEPROSY; LICHEN PLANUS; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MELANOMA; MELKERSSON ROSENTHAL SYNDROME; MOLECULAR BIOLOGY; MULTIBACILLARY LEPROSY; MULTIPLE MYELOMA; MYCOBACTERIUM LEPRAE; MYCOSIS FUNGOIDES; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; PAUCIBACILLARY LEPROSY; PHASE 1 CLINICAL TRIAL (TOPIC); PORPHYRIA CUTANEA TARDA; PREGNANCY; PRURIGO NODULARIS; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; SARCOIDOSIS; SCHNITZLER SYNDROME; SKIN ALLERGY; SKIN BIOPSY; SKIN CANCER; SKIN INFLAMMATION; SKIN LUPUS ERYTHEMATOSUS; TH1 TH2 BALANCE; TH17 CELL; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT RESPONSE; UREMIC PRURITUS; DERMATITIS; ERYTHEMA NODOSUM; IMMUNOLOGY; SKIN TUMOR;

BEHCET SYNDROME; DERMATITIS; ERYTHEMA NODOSUM; HUMANS; IMMUNOMODULATION; LUPUS ERYTHEMATOSUS, CUTANEOUS; LYMPHOMA, T-CELL, CUTANEOUS; SARCOIDOSIS; SKIN NEOPLASMS; THALIDOMIDE;

EID: 77955866153     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (241)

1. Mellin GW, Katzenstein M. The saga of thalidomide.Neurpopathy to embryopathy, with case reports of congenital abnormalities. N Engl J Med. 1962;267:1184-1193.
2. Faver IR, Guerra SG, Su WP, et al. Thalidomide for dermatology: A review of clinical uses and adverse effects. Int J Dermatol. 2005;44(1):61-67. (Pubitemid 40201995)
3. Wu JJ, Huang DB, Pang KR, et al. Thalidomide: Dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005;153(2):254-273. (Pubitemid 41228421)
4. Paghdal KV, Schwartz R. Thalidomide and its dermatologic uses. Acta Dermatovenerol Croat. 2007;15(1):39-44. (Pubitemid 46649172)
5. Stirling D, Sherman M, Strauss S. Thalidomide. A surprising recovery. J Am Pharm Assoc (Wash). 1997;37(3):306-313.
6. Lenz W. A short history of thalidomide embryopathy. Teratology. 1988;38(3):203-215.
7. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;2:1358.
8. Kelsey FO. Drug Embryopathy. The thalidomide story. Md State Med J. 1963;12:594-597.
9. Moraes M, Russo G. Thalidomide and its dermatologic uses. Am J Med Sci. 2001;321(5):321-326. (Pubitemid 32428832)
10. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 1965;6:303-306.
11. Nightingale SL. From the Food and Drug Administration: Thalidomide approved for the treatment of erythema nodosum leprosum. JAMA. 1998;280(10):872.
12. Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol. 2007;39(7-8):1489-1499. (Pubitemid 47031027)
13. Annas GJ, Elias S. Thalidomide and the Titanic: Reconstructing the technology tragedies of the twentieth century. Am J Public Health. 1999;89(1):98-101. (Pubitemid 29281980)
14. Wemambu SN, Turk JL, Waters MF, Rees R. Erythema nodosum leprosum: A clinical manifestation of the arthus phenomenon. Lancet. 1969;2:933-935.
15. Scollard DM, Bhoopat L, Kestens L, et al. Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum. Clin Immunol Immunopathol. 1992;63(3):230-236.
16. Ridley DS. The pathogenesis of the early skin lesion in leprosy. J Pathol. 1973;111(3):191-206.
17. Lai A Fat RF, Chan Pin Jin J, Van Furth R, et al. In vitro synthesis of anti-mycobacterial antibodies in biopsies from skin lesions of leprosy patients. Infect Immun. 1980;27(2):297-301. (Pubitemid 10144915)
18. Levis WR, Meeker HC, Schuller-Levis G, et al. IgM and IgG antibodies to phenolic glycolipid I from Mycobacterium leprae in leprosy: Insight into patient monitoring, erythema nodosum leprosum, and bacillary persistence. J Invest Dermatol. 1986;86(5):529-534. (Pubitemid 16052552)
19. Gusdon JP Jr, Cohen C. Effect of thalidomide on the antibody response. Am J Obstet Gynecol. 1968;100(7):952-956.
20. Shannon EJ, Miranda RO, Morales MJ, et al. Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand J Immunol. 1981;13(6):553-562. (Pubitemid 11112497)
21. The Merck Index. Whitehouse Station, NJ: Merck and Co., Inc. 1989:1458.
22. Roccaro AM, Ghobrial IM, Blotta S, et al. Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics. 2008;2(3):419-431.
23. Shannon EJ, Sandoval F. Thalidomide inhibited the synthesis of IgM and IgG whereas Thalidomide + Dexamethasone and Dexamethasone alone acted as co-stimulants with pokeweed and enhanced their synthesis. Int Immunopharmacol. 2010;10(4):487-492.
24. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173(3):699-703.
25. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis. 1993;168(2):408-414. (Pubitemid 23210619)
26. Nishimura K, Hashimoto Y, Iwasaki S. Enhancement of phorbol ester-induced production of tumor necrosis factor alpha by thalidomide. Biochem Biophys Res Commun. 1994;199(2):455-460. (Pubitemid 24181683)
27. Shannon EJ, Sandoval F. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells. Immunopharmacol Immunotoxicol. 1996;18(1):59-72. (Pubitemid 26099057)
28. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177(6):1675-1680. (Pubitemid 23146134)
29. Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, et al. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 1993;90(13):5974-5678.
30. Jacobson JM, Spritzler J, Fox L, et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. J Infect Dis. 1999;180(1):61-67. (Pubitemid 29293918)
31. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352(9140):1586-1589. (Pubitemid 28515243)
32. Villahermosa L, Tranquilino T, Fajardo J, et al. A randomized, doubleblind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. Am J Trop Med Hyg. 2005;72(5):518-526. (Pubitemid 41278818)
33. Haslett P, Roche P, Butlin C, et al. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. JID. 2005;192:2045-2053. (Pubitemid 41779200)
34. Moreira A, Kaplan G, Villahermosa L, et al. Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL. Int J Lepr. 1998;65(1):61-64.
35. Sarno EN, Grau GE, Vieira LMM, et al. Serum levels of tumor necrosis factor-alpha and interleukin-1 b during leprosy reactional states. Clin Exp Immunol. 1991;84:103-108.
36. Khanolkar-Young S, Rayment N, Brickell P, et al. Tumor necrosis factor synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol. 1995;99:196-202.
37. Shannon EJ, Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with concanavalin- A, staphylococcal entertoxin A, and purified protein derivative. Immunopharmacology. 1999;31:109-116.
38. Öyvind Ö, Riesbeck K, Qi Z, et al. Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory function in vitro. Transplant Immunol. 1996;4:117-125. (Pubitemid 26334746)
39. Shannon EJ, Asseffa A, Pankey G, et al. Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood. Immunopharmacology. 2000;46:175-179. (Pubitemid 30019258)
40. Haslett PA, Hanekom WA, Muller G, et al. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis. 2003;187: 946-55. (Pubitemid 36337907)
41. Idler I, Giannopoulos K, Zenz T, et al. Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol. 2010;148(6):948- 950.
42. Giannopoulos K, Schmitt M, Wlłasiuk P, et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia. 2008;22(1):222-224.
43. Yang Y, Zhang WG, He AL, et al. Effects of thalidomide on CD4(+) CD25(+) T regulatory cells in patients with multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008;16(3):538-542.
44. Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009;58(7):1033-1045.
45. Rodrigues GB, Passos GF, Di Giunta G, et al. Preventive and therapeutic anti-inflammatory effects of systemic and topical thalidomide on endotoxin-induced uveitis in rats. Exp Eye Res. 2007;84(3):553- 560.
46. Noman AS, Koide N, Khuda II, et al. Thalidomide inhibits lipopolysaccharide- induced nitric oxide production and prevents lipopolysaccharide- mediated lethality in mice. FEMS Immunol Med Microbiol. 2009;56(3):204-211.
47. Xu Y, Li J, Ferguson GD, Mercurio F, et al. Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood. 2009;114(2):338-45.
48. Keller M, Sollberger G, Beer HD. Thalidomide inhibits activation of caspase-1. J Immunol. 2009;183(9):5593-5599.
49. Teo SK. Properties of thalidomide and its analogues: Implications for anticancer therapy. AAPS J. 2005;7(1):E14-E19. (Pubitemid 41554303)
50. Burnet, Frank Macfarlane. Changing Patterns: An Atypical Autobiography. Melbourne, Heinemann. 1968.
51. Miller JF. Immunological function of the thymus. Lancet. 1961;2(7205):748-749.
52. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966;34(3):255-273.
53. Nathan CF, Kaplan G, Levis WR, et al. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med. 1986;315(1):6-15. (Pubitemid 16093245)
54. Nogueira N, Kaplan G, Levy E, et al. Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2. J Exp Med. 1983;158(6):2165-2170. (Pubitemid 14210812)
55. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136(7):2348- 2357.
56. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL- 12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715-725.
57. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13(8):935-943.
58. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207-1211. (Pubitemid 351543220)
59. Asarch A, Barak O, Loo DS, et al. Th17 cells: A new paradigm for cutaneous inflammation. J Dermatolog Treat. 2008;19(5):259-266.
60. Kasahara T, Hooks JJ, Dougherty SF, et al. Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol. 1983;130(4):1784-1789. (Pubitemid 13091635)
61. Nathan CF, Kaplan G, Levis WR, et al. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med. 1986;315(1):6-15. (Pubitemid 16093245)
62. Lee DJ, Li H, Ochoa MT, Tanaka M, et al. Integrated pathways for neutrophil recruitment and inflammation in leprosy. J Infect Dis. 2010;201(4):558-569.
63. Lockwood DN. Steroids in leprosy type 1 (reversal) reactions: Mechanisms of action and effectiveness. Lepr Rev. 2000;71 Suppl:S111-S114. (Pubitemid 32115012)
64. Kahawita IP, Lockwood DN. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg. 2008;102(4):329-337.
65. Taub DD, Lloyd AR, Conlon K, et al. Recombinant human interferon- inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med. 1993;177(6):1809-1814. (Pubitemid 23146150)
66. Stefani MM, Guerra JG, Sousa AL, et al. Potential plasma markers of Type 1 and Type 2 leprosy reactions: A preliminary report. BMC Infect Dis. 2009;9:75.
67. Suzuki N, Nara K, Suzuki T. Skewed Th1 responses caused by excessive expression of Txk, a member of the Tec family of tyrosine kinases, in patients with Behçet's disease. Clin Med Res. 2006;4(2):147-151. (Pubitemid 44047369)
68. Yoshimura T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford). 2009;48(4):347-354.
69. Hamzaoui K, Hamza M, Ayed K. Production of TNF-alpha and IL-1 in active Behçet's disease. J Rheumatol. 1990;17(10):1428-1429. (Pubitemid 20382885)
70. Hamzaoui K. Paradoxical high regulatory T cell activity in Behçet's disease. Clin Exp Rheumatol. 2007;25(4 Suppl 45):S107-S113.
71. Hamzaoui K, Hamzaoui A, Houman H. CD4+CD25+ regulatory T cells in patients with Behçet's disease. Clin Exp Rheumatol. 2006;24(5 Suppl 42):S71-S78. (Pubitemid 44696882)
72. Nanke Y, Kotake S, Goto M, et al. Decreased percentages of regulatory T cells in peripheral blood of patients with Behçet's disease before ocular attack: A possible predictive marker of ocular attack. Mod Rheumatol. 2008;18(4):354-358.
73. Mascaro JM, Lecha M, Torras H. Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis. Arch Dermatol. 1979;115(5):636-637. (Pubitemid 9189377)
74. Hamza M, Chaffai M, Ben Ayed H. Treatment of Behçet's syndrome with thalidomide. Nouv Presse Med. 1982;11(14):1080-1081.
75. Saylan T, Saltik I. Thalidomide in the treatment of Behçet's syndrome. Arch Dermatol. 1982;118(8):536.
76. Torras H et al. Thalidomide in the treatment of aphthosis and Behçet's disease. Four years' experience. Med Cutan Ibero Lat Amer. 1982;10(2):103-112. (Pubitemid 13169994)
77. Couzigou P et al. Thalidomide and the treatment of Behçet's syndrome. Gastroenterol Clin Biol. 1983;7(8-9):751.
78. Jorizzo JL et al. Thalidomide effects in Behçet's syndrome and pustular vasculitis. Arch Intern Med. 1986;146(5):878-881. (Pubitemid 16116664)
79. Ranselaar CG et al. Thalidomide in the treatment of neuro-Behçet's syndrome. Br J Dermatol. 1986;115(3):367-370.
80. Hamza MH. Treatment of Behçet's disease with thalidomide. Clin Rheumatol. 1986;5(3):365-371.
81. Eisenbud L, Horowitz I, Kay B. Recurrent aphthous stomatitis of the Behçet's type: Successful treatment with thalidomide. Oral Surg Oral Med Oral Pathol. 1987;64(3):289-292. (Pubitemid 17148017)
82. Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: Use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis. 1994;53(12):828-832.
83. Lewis DA, Amerasinghe CN, Murphy SM. Successful treatment of Behçet's syndrome in an African female patient with thalidomide. Int J STD AIDS. 1996;7(7):518-520.
84. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(6):443-450.
85. Green J, Upjohn E, McCormack C et al. Successful treatment of Behçet's disease with lenalidomide. Br J Dermatol. 2008;158(1):197- 198.
86. Direskeneli H, Ergun T, Yavuz S, et al. Thalidomide has both anti-inflammatory and regulatory effects in Behçet's disease. Clin Rheumatol. 2008;27(3):373-375.
87. Barnhill RL, McDougall AC. Thalidomide: Use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol. 1982;7(3):317-323. (Pubitemid 12051510)
88. Faver IR, Guerra SG, Su WP, et al. Thalidomide for dermatology: A review of clinical uses and adverse effects. Int J Dermatol. 2005;44(1):61-67. (Pubitemid 40201995)
89. Caligaris-Cappio F, Bertero MT, Converso M, et al. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol. 1995;13(3):339- 343.
90. Heine G, Sester U, Sester M, et al. A shift in the Th(1)/Th(2) ratio accompanies the clinical remission of systemic lupus erythematosus in patients with end-stage renal disease. Nephrol Dial Transplant. 2002;17(10):1790-1794. (Pubitemid 35174291)
91. Segal R, Bermas BL, Dayan M, et al. Kinetics of cytokine production in experimental systemic lupus erythematosus: Involvement of T helper cell 1/T helper cell 2-type cytokines in disease. J Immunol. 1997;158(6):3009-3016. (Pubitemid 127470564)
92. Wong CK, Ho CY, Li EK et al. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus. 2000;9(8):589-593.
93. Wong CK, Lit LC, Tam LS, et al. Hyperproduction of IL-23 and IL- 17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008;127(3):385-393.
94. Gabay C, Cakir N, Moral F, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol. 1997;24(2):303-308. (Pubitemid 27104093)
95. Zampieri S, Alaibac M, Iaccarino L, et al. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis. 2006;65(4):545-548.
96. Belmont HM, Levartovsky D, Goel A, et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40(10):1810-1816. (Pubitemid 27452531)
97. Bollain-y-Goytia JJ, Ramírez-Sandoval R, Daza L, et al. Widespread expression of inducible NOS and citrulline in lupus nephritis tissues. Inflamm Res. 2009;58(2):61-66.
98. Valencia X, Yarboro C, Illei G, et al. Deficient CD4+CD25 high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol. 2007;178(4):2579-2588. (Pubitemid 46233461)
99. Pan HF, Zhao XF, Yuan H, et al. Decreased serum IL-22 levels in patients with systemic lupus erythematosus. Clin Chim Acta. 2009;401(1-2):179-180.
100. Barba-Rubio J, Franco-Gonzalez F. Fixed lupus erythematosus (its treatment with thalidomide). Med Cutan Ibero Lat Am. 1977; 5:279-285.
101. Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol. 1983;108(4):461-466. (Pubitemid 13116922)
102. Hasper MF. Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients. Arch Dermatol. 1983;119(10):812-815. (Pubitemid 13009226)
103. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol. 1993;11(5):487-493. (Pubitemid 23328811)
104. Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients. Br J Rheumatol. 1997;36(3):353-359.
105. Sato EI, Assis LS, Lourenzi VP, et al. Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Assoc Med Bras. 1998;44(4):289-293.
106. Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol. 2000;39(3):218-222. (Pubitemid 30223891)
107. Ordi-Ros J, Cortés F, Cucurull, et al. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol. 2000;27(6):1429-1433. (Pubitemid 30354039)
108. Bohmeyer J, Achenbach A, Westenberger M, et al. Thalidomide therapy of cutaneous lupus erythematosus. Hautarzt. 2002;53(11)744-748. (Pubitemid 36069826)
109. Housman TS, Jorizzo JL, McCarty MA, et al. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol. 2003;139(1):50-54. (Pubitemid 36091574)
110. Lyakhovisky A, Baum S, Shpiro D, et al. Thalidomide therapy for discoid lupus erythematosus. Harefuah. 2006;145(7):489-492,551.
111. Cuadrado MJ, Karim Y, Sanna G, et al. Thalidomide for the treatment of resistant cutaneous lupus: Efficacy and safety of different therapeutic regimens. Am J Med. 2005;118(3):246-250. (Pubitemid 40312635)
112. Coelho A, Souto MI, Cardoso CR, et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: A 65 series of Brazilian patients. Lupus. 2005;14(6):434-439. (Pubitemid 40961316)
113. Shah A, Albrecht J, Bonilla-Martinez Z, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol. 2009;145(3):303-306.
114. Casellas AM, Prat A, Llera A, et al. Increased superoxide production by polymorphonuclear leukocytes in systemic lupus erythematosus. Clin Exp Rheumatol. 1991;9(5):511-514.
115. Alves CM, Marzocchi-Machado CM et al. Superoxide anion production by neutrophils is associated with prevalent clinical manifestations in systemic lupus erythematosus. Clin Rheumatol. 2008;27(6):701-708. (Pubitemid 351650030)
116. Perez HD, Goldstein IM. Polymorphonuclear leukocyte chemotaxis in systemic lupus erythematosus. J Rheumatol Suppl. 1987;14 Suppl 13:53-58. (Pubitemid 17118017)
117. Kontos AP, Jirsari M, Jacobsen G, et al. Immunoglobulin M predominance in cutaneous lupus erythematosus. J Cutan Pathol. 2005;32(5):352-355. (Pubitemid 40547794)
118. Cummins DL, Gaspari AA. Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus: Discordant effects on minimal erythema dose and sunburn cell formation. Br J Dermatol. 2004;151(2):458-464. (Pubitemid 39215160)
119. Kawakami K, Owan I, Kaneshima H, Saito A. Type 1-like helper T cell lines responsive to autologous peripheral blood monocytes established from two patients with sarcoidosis. Sarcoidosis. 1995;12(2):111-117.
120. Gerke AK, Hunninghake G. The immunology of Sarcoid. Clin Chest Med. 2008;29(3):379-390.
121. Miyara M, Amoura Z, Parizot C, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med. 2006;203(2):359-370. (Pubitemid 43290845)
122. Taflin C, Miyara M, Nochy D, et al. FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol. 2009;174(2):497-508.
123. Barriere H. Cutaneous sarcoidosis. Treatment with thalidomide. Presse Med. 1983;12(15):963.
124. Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol. 1995;32(5 Pt 2):866-869.
125. Rousseau L, Beylot-Barry M, Doutre MS, et al. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol. 1998;134(8):1045-1046. (Pubitemid 28385340)
126. Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: A case report. J Am Acad Dermatol. 1998;39(5 Pt 2):835-838. (Pubitemid 28520697)
127. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest. 2002;122(1):227-232. (Pubitemid 34754167)
128. Nguyen YT, Dupuy A, Cordoliani F, et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol. 2004;50(2):235- 241.
129. Ye Q, Chen B, Tong Z, et al. Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J. 2006;28(4):824-831. (Pubitemid 46335531)
130. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigenstimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol. 1995;99(2):160-167.
131. Oliver SJ, Kikuchi T, Krueger JG, et al. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol. 2002;102:225-236. (Pubitemid 34259256)
132. Papadavid E, Economidou J, Psarra A, et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2003;148(4):709-718. (Pubitemid 36629749)
133. Berger CL, Tigelaar R, Cohen J, et al. Cutaneous T-cell lymphoma: Malignant proliferation of T-regulatory cells. Blood. 2005;105(4):1640-1647. (Pubitemid 40223685)
134. Wada DA, Wilcox RA, Weenig RH, Gibson LE. Paucity of intraepidermal FoxP3-positive T cells in cutaneous T-cell lymphoma in contrast with spongiotic and lichenoid dermatitis. J Cutan Pathol. 2010;37(5):535-541.
135. Tiemessen MM, Mitchell TJ, Hendry L, et al. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol. 2006;126(10):2217-2223. (Pubitemid 44413168)
136. Gjerdrum LM et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: Association with disease stage and survival. Leukemia. 2007;21(12):2512-2518. (Pubitemid 350148895)
137. Brightman L, Demierre MF. Thalidomide in mycosis fungoides. J Am Acad Dermatol. 2005;52(6):1100-1101.
138. Oxberry SG et al. Response to thalidomide in chemotherapy-resistant cutaneous T-cell lymphoma. Clin Oncol. 2006;18(1):86-87. (Pubitemid 43056706)
139. Deng L, Ding W, Granstein RD. Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. J Invest Dermatol. 2003;121:1060-1065. (Pubitemid 37430974)
140. Haslett PA, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD81 subset. J Exp Med. 1998;187:1885-1892. (Pubitemid 28262451)
141. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med. 2004;350:1978-1988. (Pubitemid 38580201)
142. Kharkevitch DD, Seito D, Balch GC, et al. Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Int J Cancer. 1994;58(3):317-323. (Pubitemid 24254637)
143. Lauerova L, Dusek L, Simickova M, et al. Malignant melanoma associates with Th1/Th2 imbalance that coincides with distreatease progression and immunotherapy response. Neoplasma. 2002;49(3):159-166. (Pubitemid 34728793)
144. Nevala WK, Vachon CM, Leontovich AA, et al. Melanoma Study Group of the Mayo Clinic Cancer Center. Evidence of systemic Th2- driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res. 2009;15(6):1931-1939.
145. Su X, Ye J, Hsueh EC, Zhang Y, et al. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol. 2010;184(3):1630-1641.
146. Viguier M, Lemaître F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173(2):1444-1453. (Pubitemid 38924326)
147. Gutman M, Szold A, Ravid A, et al. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res. 1996;16(6B):3673-3677. (Pubitemid 27085031)
148. Eisen T, Boshoff C, Mak I, et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer. 2000;82(4):812-817. (Pubitemid 30085231)
149. Hwu WJ. New approaches in the treatment of metastatic melanoma: Thalidomide and temozolomide. Oncology (Williston Park). 2000;14(12 Suppl 13):25-28.
150. Hwu WJ, Raizer J, Panageas KS, et al. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol. 2001;2(10):634-635. (Pubitemid 32998544)
151. Hwu WJ, Krown SE, Panageas KS, et al. Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dosefinding trial. J Clin Oncol. 2002;20(11):2610-2615. Erratum in: J Clin Oncol. 2002;20(15):3361. (Pubitemid 34575632)
152. Lee DS, DiVito J Jr, Bui AH, et al. Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide. J Pediatr Hematol Oncol. 2002;24(6):488-491.
153. Palencia G, Arrieta O, Ríos C, et al. Effect of thalidomide in different tumors in rodents. J Exp Ther Oncol. 2002;2(3):158-162. (Pubitemid 34663461)
154. Danson S, Lorigan P, Arance A, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol. 2003;21(13):2551- 3557.
155. Hwu WJ, Krown SE, Menell JH, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003;21(17):3351-3356. (Pubitemid 46606269)
156. Hwu WJ, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: A phase II study. Cancer. 2005;103(12):2590-3597.
157. Heere-Ress E, Boehm J, Thallinger C, et al. Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model. J Invest Dermatol. 2005;125(2):201-206. Erratum in: J Invest Dermatol. 2005;125(6):1320. (Pubitemid 41648150)
158. Mita MM, Rowinsky EK, Forero L, et al. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2007;59(2):165-174. (Pubitemid 44885146)
159. Laber DA, Okeke RI, Arce-Lara C, et al. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. J Cancer Res Clin Oncol. 2006;132(9):611-616. (Pubitemid 44078530)
160. Kawamata A, Ito D, Odani T, et al. Thalidomide suppresses melanoma growth by activating natural killer cells in mice. Oncol Rep. 2006;16(6):1231-1236.
161. Vestermark LW, Larsen S, Lindeløv B, et al. A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncol. 2008;47(8):1526-1530.
162. Pawlak WZ, Legha SS. Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res. 2004;14(1):57-62. (Pubitemid 38392415)
163. Reiriz AB, Richter MF, Fernandes S, et al. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res. 2004;14(6):527-531. (Pubitemid 40221145)
164. Vaishampayan UN, Heilbrun LK, Marsack C, et al. Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma. Anticancer Drugs. 2007;18(10):1221-1226. (Pubitemid 47480748)
165. Krown SE, Niedzwiecki D, Hwu WJ, et al. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer. 2006;107(8):1883-1890. (Pubitemid 44582959)
166. Hutchins LF, Moon J, Clark JI, et al. Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer. 2007;110(10):2269-2275. (Pubitemid 350103469)
167. Atkins MB, Sosman JA, Agarwala S, et al. Temozolomide, thalidomide, and
168. Ott PA, Chang JL, Oratz R, et al. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. Chemotherapy. 2009;55(4):221-227.
169. Bartlett JB, Michael A, Clarke IA, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004;90(5):955- 961.
170. Sharma RA, Steward WP, Daines CA, et al. Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer. 2006;42(14):2318-2325. (Pubitemid 44307625)
171. Mangiameli DP, Blansfield JA, Kachala S, et al. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med. 2007;5:38.
172. Lu L, Payvandi F, Wu L, Zhang LH, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009;77(2):78-86.
173. Glaspy J, Atkins MB, Richards JM, et al. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer. 2009;115(22):5228-5236.
174. Eisen T, Trefzer U, Hamilton A, et al. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer. 2010;116(1):146-154
175. Zhang S, Li M, Gu Y, et al. Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J Exp Clin Cancer Res. 2008;27:60.
176. Giannopoulos K, Schmitt M, Własiuk P, et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia. 2008;22(1):222-224.
177. Zhao Y, Balato A, Fishelevich R, et al. Th17/Tc17 infiltration and associated cytokine gene expression in elicitation phase of allergic contact dermatitis. Br J Dermatol. 2009;16(6):1301-1306.
178. Larsen JM, Bonefeld CM, Poulsen SS, et al. IL-23 and T(H)17-mediated inflammation in human allergic contact dermatitis. J Allergy Clin Immunol. 2009;123(2):486-492.
179. Martiniuk F, Lee DS, Gaspari A, et al. Expression of CD70 and the TH17 transcription factor RORgammaT in human contact dermatitis. J Drugs Dermatol. 2008;7(10):956-960.
180. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickelspecific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: Synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol. 1999;162(1):494-502. (Pubitemid 29018959)
181. Ricciardi L, Minciullo PL, Saitta S, et al. Increased serum levels of IL-22 in patients with nickel contact dermatitis. Contact Dermatitis. 2009;60(1):57-58.
182. Moed H, Von Blomberg BM, Bruynzeel DP, et al. Regulation of nickel-induced T-cell responsiveness by CD4+CD25+ cells in contact allergic patients and healthy individuals. Contact Dermatitis. 2005;53(2):71-74. (Pubitemid 41039715)
183. O'Connor W Jr, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009;10(6):603-609.
184. Gober MD, Gaspari AA. Allergic contact dermatitis. Curr Dir Autoimmun. 2008;10:1-26.
185. Neparidze N, Dhodapkar MV. Harnessing CD1d-restricted T cells toward antitumor immunity in humans. Ann N Y Acad Sci. 2009;1174:61-67.
186. Chen L, Martinez O, Overbergh L, Mathieu C, et al. Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clin Exp Immunol. 2004;138(3):375-387. (Pubitemid 39573615)
187. Toda M, Leung DY, Molet S, et al. Polarized in vivo expression of IL- 11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol. 2003;111(4):875-881. (Pubitemid 36470263)
188. Koga C, Kabashima K, Shiraishi N, et al. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128(11):2569-2571.
189. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol. 2008;181(10):7420-7427.
190. Ou LS, Goleva E, Hall C, et al. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol. 2004;113(4):756-763. (Pubitemid 38530433)
191. Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 2009;123(6):1244-1252.
192. Sosa M, Flores G, Estrada S, et al. Comparative treatment between thalidomide and transfer factor in severe atopic dermatitis. Rev Alerg Mex. 2001;48(2):56-64.
193. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207-1211. (Pubitemid 351543220)
194. Haider AS, Lowes MA, Suárez-Fariñas M, et al. Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol. 2008;180(3):1913-1920.
195. Boniface K, Guignouard E, Pedretti N, et al. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol. 2007;150(3):407-415. (Pubitemid 350098734)
196. Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+ CD25 high regulatory T cells in psoriasis: Mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol. 20051;174(1):164-173.
197. Goodman WA, Levine AD, Massari JV, et al. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol. 2009;183(5):3170-3176.
198. Dobson CM, Parslew RA. Exacerbation of psoriasis by thalidomide in Behçet's syndrome. Br J Dermatol. 2003;149(2):432-433. (Pubitemid 37100284)
199. Varma K, Finlay AY. Exacerbation of psoriasis by thalidomide in a patient with erythema multiforme. Br J Dermatol. 2006;154(4):789- 790.
200. Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008;24(5):1529-1538. (Pubitemid 351741586)
201. Londoño F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol. 1973;12(5):326-328.
202. Lovell CR, Hawk JL, Calnan CD, et al. Thalidomide in actinic prurigo. Br J Dermatol. 1983;108(4):467-471. (Pubitemid 13116923)
203. Estrada-G I, Garibay-Escobar A, Núñez-Vázquez A, et al. Evidence that thalidomide modifies the immune response of patients suffering from actinic prurigo. Int J Dermatol. 2004;43(12):893-897. (Pubitemid 39642314)
204. Misery L, Larbre B, Lyonnet S, et al. Remission of Langerhans cell histiocytosis with thalidomide treatment. Clin Exp Dermatol. 1993;18(5):487. (Pubitemid 23285488)
205. Thomas L, Ducros B, Secchi T, et al. Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review. Arch Dermatol. 1993;129(10):1261-1264. (Pubitemid 23296735)
206. Meunier L, Marck Y, Ribeyre C, et al. Adult cutaneous Langerhans cell histiocytosis: Remission with thalidomide treatment. Br J Dermatol. 1995;132(1):168.
207. Broekaert SM, Metzler G, Burgdorf W, et al. Multisystem Langerhans cell histiocytosis: Successful treatment with thalidomide. Am J Clin Dermatol. 2007;8(5):311-314. (Pubitemid 47533558)
208. Grinspan D, Blanco GF, Agüero S. Treatment of aphthae with thalidomide. J Am Acad Dermatol. 1989;20(6):1060-1063. (Pubitemid 19151515)
209. Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol. 1990;126(7):923-927. (Pubitemid 20224550)
210. Shetty K. Thalidomide in the management of recurrent aphthous ulcerations in patients who are HIV-positive: A review and case reports. Spec Care Dentist. 2005;25(5):236-234.
211. Bahmer FA, Zaun H, Luszpinski P. Thalidomide treatment of recurrent erythema multiforme. Acta Derm Venereol. 1982;62(5):449-450. (Pubitemid 12024340)
212. Conejo-Mir JS, Del Canto S, Muñoz MA, et al. Thalidomide as elective treatment in persistent erythema multiforme; Report of two cases. J Drugs Dermatol. 2003;2(1):40-44.
213. Chen CW, Tsai TF, Chen YF, et al. Persistent erythema multiforme treated with thalidomide. Am J Clin Dermatol. 2008;9(2):123-127.
214. Seyahi E, Ozdogan H, Masatlioglu S, et al. Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient. Clin Exp Rheumatol. 2002;20(4 Suppl 26):S43-S44.
215. Lim SH, McWhannell A, Vora AJ, et al. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation. Lancet. 1988;1(8577):117. (Pubitemid 18027970)
216. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992;326(16):1055-1058.
217. Staumont-Sallé D, Magro L, Piette F, et al. Chronic graft-versus-host disease revealed by lichenoid vulvar lesions successfully treated with thalidomide. Acta Derm Venereol. 2003;83(4):302-303. (Pubitemid 36920612)
218. Moulin G, Bonnet F, Barrut D, et al. Treatment of Jessner-Kanof disease with thalidomide. Ann Dermatol Venereol. 1983;110(8):611- 614.
219. Guillaume JC, Moulin G, Dieng MT, et al. Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltration of the skin. Arch Dermatol. 1995;131(9):1032-1035.
220. Solèr RA, Howard M, Brink NS, et al. Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin Infect Dis. 1996;23(3):501-503.
221. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDSrelated Kaposi's sarcoma. J Clin Oncol. 2000;18(13):2593-2602. (Pubitemid 30432526)
222. Rubegni P, Sbano P, De Aloe G, et al. Thalidomide in the treatment of Kaposi's sarcoma. Dermatology. 2007;215(3):240-244. (Pubitemid 47378993)
223. Pérez Alfonzo R, Weiss E, Piquero Martín J, et al. Generalized lichen planus with erosive lesions of the penis, treated with thalidomide. Report of a case and review of the literature. Med Cutan Ibero Lat Am. 1987;15(4):321-326.
224. Dereure O, Basset-Seguin N, Guilhou JJ. Erosive lichen planus: Dramatic response to thalidomide. Arch Dermatol. 1996;132(11):1392- 1393.
225. Camisa C, Popovsky JL. Effective treatment of oral erosive lichen planus with thalidomide. Arch Dermatol. 2000;136(12):1442-1443. (Pubitemid 32009264)
226. Maender JL, Krishnan RS, Angel TA, et al. Complete resolution of generalized lichen planus after treatment with thalidomide. J Drugs Dermatol. 2005;4(1):86-88.
227. Moura AK, Moure ER, Romiti R. Treatment of cutaneous lichen planus with thalidomide. Clin Exp Dermatol. 2009;34(1):101-103.
228. Safa G, Joly P, Boullie MC, et al. Melkersson-Rosenthal syndrome treated by thalidomide. 2 cases. Ann Dermatol Venereol.1995;122(9):609-611. (Pubitemid 26018687)
229. Medeiros M Jr, Araujo MI, Guimarães NS, et al. Therapeutic response to thalidomide in Melkersson-Rosenthal syndrome: A case report. Ann Allergy Asthma Immunol. 2002;88(4):421-424.
230. Monastirli A, Georgiou S, Bolsen K, et al. Treatment of porphyria cutanea tarda with oral thalidomide. Skin Pharmacol Appl Skin Physiol. 1999;12(6):305-311. (Pubitemid 29495439)
231. Sheskin J. Treatment of prurigo nodularis Hyde using thalidomide. Hautarzt. 1975 Apr;26(4):215-7.
232. Van den Broek H. Treatment of prurigo nodularis with thalidomide. Arch Dermatol. 1980;116(5):571.
233. Maurer T, Poncelet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: Efficacy and risk of neuropathy. Arch Dermatol. 2004;140(7):845-849. (Pubitemid 38917853)
234. Lan CC, Lin CL, Wu CS, et al. Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide. J Dermatol. 2007;34(4):237-242.
235. Orlando A, Renna S, Cottone M. Prurigo nodularis of Hyde treated with low-dose thalidomide. Eur Rev Med Pharmacol Sci. 2009;13(2):141-145.
236. Munro CS, Cox NH. Pyoderma gangrenosum associated with Behçet's syndrome-Response to thalidomide. Clin Exp Dermatol. 1988;13(6):408-410.
237. Hecker MS, Lebwohl MG. Recalcitrant pyoderma gangrenosum: treatment with thalidomide. J Am Acad Dermatol. 1998;38(3):490- 491.
238. Federman GL, Federman DG. Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin Proc. 2000;75(8):842-844. (Pubitemid 30640644)
239. Worm M, Kolde G. Schnitzler's syndrome: Successful treatment of two patients using thalidomide. Br J Dermatol. 2003;148(3):601- 602.
240. De Koning HD, Bodar EJ, Simon A, et al. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis. 2006;65(4):542-544.
241. Silva SR, Viana PC, Lugon NV, et al. Thalidomide for the treatment of uremic pruritus: A crossover randomized double-blind trial. Nephron. 1994;67(3):270-273. (Pubitemid 24177633)